



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C12N 15/10, C12Q 1/68</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 95/11971</b> (43) International Publication Date: 4 May 1995 (04.05.95)</p>
<p>(21) International Application Number: PCT/US94/12505 (22) International Filing Date: 28 October 1994 (28.10.94) (30) Priority Data: 08/142,124 28 October 1993 (28.10.93) US (71) Applicant: LIFE TECHNOLOGIES, INC. [US/US]; 8717 Grovemont Circle, Gaithersburg, MD 20877 (US). (72) Inventor: HARTLEY, James, L.; 7409 Hillside Drive, Frederick, MD 21702 (US). (74) Agents: ESMOND, Robert, W. et al.; Sterne, Kessler, Gold- stein &amp; Fox, Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).</p>		<p>(81) Designated States: European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: NUCLEIC ACID MARKER LADDER FOR ESTIMATING MASS

(57) Abstract

The invention relates to a nucleic acid marker ladder which is a restriction endonuclease digest, wherein a nucleic acid restriction endonuclease digest is a collection of nucleic acid fragments resulting from complete digestion of one or more nucleic acids by one or more restriction endonucleases; the restriction endonuclease digest contains at least 3 fragments; and the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.



-1-

## Nucleic Acid Marker Ladder For Estimating Mass

### *Field of the Invention*

5 The present invention is in the field of molecular biology and specifically relates to the technique of gel electrophoresis of nucleic acid fragments.

### *Background of the Invention*

10 Gel electrophoresis of nucleic acid is a well known technique in molecular biology. Nucleic acid molecules are separated on the basis of size (length or molecular weight), and conformation (linear vs. nicked circles vs. covalently closed circles). For a given conformation, electrophoretic mobility is inversely related to size.

15 Conventional agarose gel electrophoresis is commonly used for the separation of nucleic acid fragments within a practical resolution limit of 50 kbp (Cantor, C.R. and Schimmel, P.R. (1980) *Biophysical Chemistry*, Vol. III, pp. 1012-1036, Freeman, San Francisco; and Maniatis, T. *et al.* (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). A method called pulsed field gel electrophoresis (PFGE) has been developed to provide separation of DNA  
20 molecules up to 2 Mbp (Schwartz, D.C. *et al.* (1983) *Cold Spring Harbor Symp. Quant. Biol.* 47:189-195.; and Schwartz, D.C. and Cantor, C.R. (1984) *Cell* 37:67-75).

25 A number of mixtures of nucleic acid fragments ("ladders") are commercially available that can be used as markers for determining or estimating the sizes of nucleic acid molecules during gel electrophoresis. One type of ladder is constructed by digesting plasmids or bacteriophage with one or more restriction enzymes. The size of the marker fragments will depend upon the natural location of the restriction enzyme site within the molecule to

- 2 -

be digested and will produce a quasi-random size distribution. For example digestion of bacteriophage  $\lambda$  (*lambda*) with *Hind*III produces fragments of 23,130, 9,416, 6557, 4361, 2322, 2027, 564, and 125 base pairs (bp) (See Cat. No. 5612SA, Life Technologies, Inc. 1992 catalogue, Gaithersburg, MD, p. 318).

Alternatively, a ladder may comprise fragments which vary linearly with molecular weight, i.e. adjacent bands may differ by about 1000 base pairs (e.g. "1 Kb DNA Ladder", See Cat. No. 5615SA, Life Technologies, Inc. 1992 catalogue, Gaithersburg, MD, p. 323), 100 base pairs (e.g. "100 bp DNA Ladder", See Cat. No. 5628SA, Life Technologies, Inc. 1992 catalogue, Gaithersburg, MD, p. 322), or 123 bp (e.g. "123 bp DNA Ladder", See Cat. No. 5613SA, Life Technologies, Inc. 1992 catalogue, Gaithersburg, MD, p. 323). Some ladders have been constructed and sold that are logarithmically spaced ("GenePrint™", cat. no. DG1911, Promega, Madison, WI).

Nucleic acid is visualized in agarose gels following electrophoresis by staining with the fluorescent dye ethidium bromide (Sharp *et al.* (1973) *Biochemistry* 12:3055). Ethidium bromide contains a planar group that intercalates between nucleic acid bases. The fixed position of this planar group and its close proximity to the nucleic acid bases cause the ethidium bromide bound to the nucleic acid to display an increased fluorescent yield compared to that of ethidium bromide in free solution (See Sambrook *et al.* (1989) *Molecular Cloning*, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, page 6.15). The molecular mass of a nucleic acid fragment can be determined following agarose gel electrophoresis and ethidium bromide staining by comparing the intensity of the fluorescence of a fragment of unknown molecular mass with the intensity of a similarly sized fragment of known molecular mass.

### *Summary of the Invention*

In general, the present invention provides a nucleic acid marker ladder. More specifically, the present invention provides a nucleic acid marker ladder consisting essentially of a restriction endonuclease digest wherein

5 (a) the nucleic acid restriction endonuclease digest is a collection of nucleic acid fragments resulting from the complete digestion of one or more nucleic acids by one or more restriction endonucleases;

(b) the restriction endonuclease digest contains at least 3 fragments; and

10 (c) the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.

The present invention also provides a nucleic acid marker kit comprising a carrier means having in close confinement therein at least one container means where a first container means contains the above-described nucleic acid marker ladder.

15 The present invention also provides a method of preparing a nucleic acid marker ladder comprising:

(a) generating at least two polymerase chain reaction (PCR) products wherein each product is generated from a template comprising a restriction endonuclease site and a primer comprising the restriction endonuclease site in the template;

20 (b) joining the PCR products to produce one or more nucleic acid molecules; and

(c) completely digesting the nucleic acid molecules with at least one restriction endonuclease

25 wherein a nucleic acid marker ladder is produced wherein the ladder contains at least 3 fragments and the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.

30 Further objects and advantages of the present invention will be clear from the description that follows.

- 4 -

### *Brief Description of the Figures*

FIGURE 1. A plasmid map of pML1 (Mass Ladder).

FIGURE 2. Restriction enzyme digest of pML1. Lane 1. 100 bp ladder (See Cat. No. 5628SA, Life Technologies, Inc. 1992 catalogue, Gaithersburg, MD, p. 322); Lanes 2, 4-6, 8-9. *SspI* digest of pML1.

### *Detailed Description of the Invention*

The present invention relates to a nucleic acid marker ladder.

In one embodiment, the present invention relates to a nucleic acid marker ladder consisting essentially of a restriction endonuclease digest, wherein

(a) the nucleic acid restriction endonuclease digest is a collection of nucleic acid fragments resulting from the complete digestion of one or more nucleic acids by one or more restriction endonucleases;

(b) the restriction endonuclease digest contains at least 3 fragments; and

(c) the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more. In one preferred embodiment the integer is 10. In another preferred embodiment, the integer is 25. In yet another preferred embodiment, the integer is 50. In a further embodiment, the integer is 100. In another preferred embodiment, the collection of nucleic acid fragments results from digestion of a nucleic acid by one restriction endonuclease. In a further preferred embodiment, the nucleic acid is DNA. One skilled in the art would recognize that the size of the fragments can be approximately a multiple of an integer. For example, the fragment's size can be 101, 201, 301, and 401 bp.

- 5 -

In another embodiment, the present invention relates to a nucleic acid marker kit comprising a carrier means having in close confinement/therein at least one container means where a first container means contains the above-described nucleic acid marker ladder.

5           A restriction endonuclease (also restriction enzyme) is an enzyme that has the capacity to recognize a specific base sequence (usually 4, 5, or 6 base pairs in length) in a DNA molecule, and to cleave the DNA molecule where this sequence appears. For example, *EcoRI* recognizes the base sequence GAATTC/CTTAAG.

10           The DNA molecules produced by digestion with a restriction endonuclease are referred to as restriction fragments. Any given genome, plasmid or phage may be digested by a particular restriction endonuclease into a discrete set of restriction fragments.

15           The most commonly used analytical method (though not the only one) for fractionating double-stranded DNA molecules on the basis of size is agarose gel electrophoresis. The principle of this method is that DNA molecules migrate through the gel as though it were a sieve that retards the movement of the largest molecules to the greatest extent and the movement of the smallest molecules to the least extent. Note that the smaller the DNA  
20           fragment, the greater the mobility under electrophoresis in the agarose gel. The DNA fragments fractionated by agarose gel electrophoresis can be visualized directly by a staining procedure if the number of fragments included in the pattern is small. Preferably, the nucleic acid-containing agarose gel is stained with ethidium bromide.

25           As will be understood by those of skill in the art, the nucleic acid molecules used to form the marker ladder are preferably any linear or circular DNA which is cleavable by a restriction enzyme. For example, the nucleic acid may be chromosomes, plasmids, cosmids or viral nucleic acid. Preferably, the nucleic acid molecules are plasmid or viral molecules and  
30           derivatives thereof. The nucleic acid present in the plasmid or viral molecule may include exogenous nucleic acid which has been joined to produce the

- 6 -

plasmid or viral molecule. In one preferred embodiment, the nucleic acid is DNA.

In another embodiment, the present invention relates to a method of preparing a nucleic acid marker ladder comprising:

5 (a) generating at least two polymerase chain reaction (PCR) products wherein each product is generated from a template comprising a restriction endonuclease site and a primer comprising the restriction endonuclease site in the template;

10 (b) joining the PCR products to produce one or more nucleic acid molecules; and

(c) completely digesting the nucleic acid molecules with at least one restriction endonuclease

15 wherein a nucleic acid marker ladder is produced wherein the ladder contains at least 3 fragments and the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.

To construct a nucleic acid molecule which when digested with a restriction endonuclease produces the marker ladder of the present invention, the number of fragments in the restriction endonuclease digest and the desired size of the fragments are selected. In one preferred embodiment, the  
20 restriction endonuclease digest contains at least three fragments. In another preferred embodiment, the restriction endonuclease digest contains 3, 4, 6, 8 or 10 fragments. In a further preferred embodiment, the restriction endonuclease digest contains 6 fragments.

25 The size of the fragments in base pairs is preferably selected to be a multiple of an integer, wherein the integer is 10 or more. In one preferred embodiment, the integer is 10, 25, 50, or 100. In another preferred embodiment, the integer is 100.

30 Preferably, one of the fragments contains an origin of replication (for example, *ori*) such that the nucleic acid molecule may autonomously replicate within a cell. It is also preferable that one of the fragments contains a selectable or screenable marker. The origin of replication and the marker may

- 7 -

be present on the same fragment. Transformants containing this DNA fragment may be cultured and selected with a selection agent corresponding to the selectable marker.

5 The nucleic acid molecule is preferably constructed from polymerase chain reaction (PCR) products. The polymerase chain reaction provides a method for selectively increasing the concentration of a nucleic acid molecule having a particular sequence even when that molecule has not been previously purified and is present only as a single copy in a particular sample. The method can be used to amplify single or double stranded nucleic acid.  
10 Reviews of the polymerase chain reaction are provided by Mullis, K.B., *Cold Spring Harbor Symp. Quant. Biol.* 51:263-273 (1986); Saiki, R.K., *et al.*, *Bio/Technology* 3:1007-1012 (1985); Mullis, K.B., *et al.*, *Methods in Enzymology* 155:350 (1987); Mullis, K., *et al.*, U.S. Patent No. 4,683,202; Erhlich, H., U.S. Patent No. 4,582,788; and Saiki, R., *et al.*, U.S. Patent  
15 No. 4,683,194.

In one preferred embodiment, a PCR product has the desired restriction endonuclease site internally. In another preferred embodiment, a PCR product has the desired restriction endonuclease site at the right and/or left end of the PCR product. In a further preferred embodiment, the PCR product has the  
20 desired restriction endonuclease site internally and at the right or left end of the PCR product.

The PCR product is preferably generated from a naturally occurring template. The template is preferably plasmid, phage, or plant, animal, or bacterial genomic DNA. The template preferably has an internal restriction  
25 endonuclease site. The desired restriction endonuclease site at the right or left end of the PCR product is preferably generated by a restriction endonuclease site in the PCR primer.

The spacing of the PCR priming sites and the naturally occurring restriction sites is preferably arranged so that when the PCR products are  
30 joined together, the nucleic acid molecule so formed when harvested from



- 8 -

*E. coli* can be cut with the desired restriction endonuclease to produce the digest of the present invention.

For example, if a ladder of 6 fragments is preferred, three PCR products may be joined together. Product 1 would preferably contain joinable ends A and C, wherein C contains the desired restriction endonuclease site. Product 1 would also preferably contain the desired restriction endonuclease site (B) internally.

Product 1    A       B       C

Product 2 would preferably contain joinable ends D and F, wherein F contains the desired restriction endonuclease site. Product 2 would also preferably contain the desired restriction endonuclease site (E) internally.

Product 2    D       E       F

Product 3 would preferably contain joinable ends G and I, wherein I contains the desired restriction endonuclease site. Product 3 would also preferably contain the desired restriction endonuclease site (H) internally.

Product 3    G       H       I.

The primer ends are constructed such that C is joinable to D, F is joinable to G, and I is joinable to A. The primer ends A, C, D, F, G, and I are variable and depend upon the desired size of the fragments present in the digest.

The PCR products can be joined together using ligase (preferably, *E. coli* DNA ligase, Cat. No. 8052SA, Life Technologies, Inc., Gaithersburg, MD) to produce a nucleic acid molecule. The molecule is then digested with at least one restriction endonuclease wherein a nucleic acid marker ladder is produced wherein the ladder contains at least 3 fragments and the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more. Preferably, one restriction endonuclease is used. The six fragments produced from digestion of the above-described molecule are B-C, C-E, E-F, F-H, H-I, and I-B.

In the examples that follow, DNA from three sources was joined together to form a nucleic acid which when cleaved with a restriction enzyme

- 9 -

produces a marker ladder of 6 fragments wherein the fragments are multiples of 100.

The present invention is useful as a standard to be used during electrophoresis. A marker ladder wherein the size of the fragments is a multiple of an integer (preferably an integer of 10 or more) is extremely convenient and easy to use since one skilled in the art can quickly calculate the size of an unknown nucleic acid fragment.

However, the marker ladder of the present invention not only allows one to size a nucleic acid but also to determine the mass of the nucleic acid. The molecular mass of a nucleic acid fragment can be determined following agarose gel electrophoresis and ethidium bromide staining by comparing the intensity of the fluorescence of a fragment of unknown molecular mass with the intensity of a similarly sized fragment of known molecular mass. The molecular mass is easily determined because all of the fragments derive from a single nucleic acid molecule.

The present invention is described in further detail in the following non-limiting examples.

#### *Example 1*

##### *Construction of an SspI Marker Ladder*

A marker ladder was constructed from three PCR products. Each PCR product has an *Ssp* I at its right end, and an internal *Ssp* I site (naturally occurring in the DNA template). The spacing of the priming sites and the naturally occurring restriction sites was arranged so that when the three PCR fragments were annealed together (uracil bases in the 5' ends of the primers, treated with uracil DNA glycosylase (Life Technologies, Inc., Gaithersburg, MD); 3' ends anneal; U.S. Patent Nos. 5,137,814 and 5,229,283) to form a circular molecule, the plasmid so formed when harvested from *E. coli* can be cut (to completion) into six *Ssp* I fragments, all of which are multiples of 100 bp.

- 10 -

Three polymerase chain reactions were performed with each of the following three sets of primers:

- 5                   A           Spacer           pUC coord. 525  
pUC left [SEQ ID NO:1]: 5' [auc uga ccu cau] [aat tta] [cgg aag cat aaa gtg taa agc ct] 3'
- B'           *Ssp* I           pUC coord. 2600  
pUC right [SEQ ID NO:2]: 5' [agu cac agc uau] [aat att] [ gga aat gtg cgc gga acc cc] 3'
- B           Spacer           Ad2 coord. 32645  
Adeno2 left [SEQ ID NO:3]: 5'[aua gcu gug acu] [aat tta] [cta gtg aat cca cag aaa cta gc] 3'
- 10                  C'           *Ssp* I           Ad2 coord. 34620  
Adeno2 right [SEQ ID NO:4]: 5' [aca ucu gga cuu] [aat att] [aga cat att gat aag gtg gcg ag] 3'
- C           Spacer           SV40 coord. 1127  
SV40 Left [SEQ ID NO:5]: 5' [aag ucc aga ugu] [aat tta] [ggg aca gtt tgg caa ggt ttt ta] 3'
- A'           *Ssp* I           SV40 coord. 1702  
SV40 right [SEQ ID NO:6]: 5' [aug agg uca gau] [aat att] [taa gcc ttt ttg atg ttc atc agg] 3'

15                   Each 50  $\mu$ l polymerase chain reaction contained 0.3  $\mu$ M of each primer (reaction (a) contained the pUC primers; reaction (b) contained the Adeno2 primers; and reaction (c) contained the SV40 primers), 1  $\mu$ l AmpliTaq (Perkin Elmer Cetus), 1 ng of template DNA (SV40 cut with *Kpn* I; Adenovirus 2; or pUC19 cut with *Eco*RI (all DNAs from Life Technologies, Inc., Gaithersburg, MD)) and 1 X PCR buffer (50 mM KCl, 10 mM Tris HCl pH 8.3, 1.5 mM MgCl<sub>2</sub>, 5 mM 2-mercaptoethanol). Cycling conditions were 94° 5 min; thirty

20                   cycles of 94° 30 sec, 55° 30 sec. 72° 2 min; and hold at 0°.

                  UDG cloning was used to clone the PCR products. One  $\mu$ l of each PCR product was combined with 14  $\mu$ l water, 2  $\mu$ l 10 X PCR buffer, and 1

25                    $\mu$ l = 1 unit UDG (Life Technologies, Inc., Gaithersburg, MD), incubated 37° 30 min, and transformed 1  $\mu$ l into DH5 alpha cells (Life Technologies, Inc., Gaithersburg, MD). About 2500 colonies were obtained. Twelve colonies were picked for minipreps. Of these twelve, eleven gave the expected 6 *Ssp* I fragments of the expected size.

- 11 -

One of these plasmids was chosen and named "pML1". This plasmid is exactly 4700 bp, and contains six *Ssp* I (blunt) fragments, of sizes 2000, 1200, 800, 400, 200 and 100 bp. Thus, when 470 ng of this complete digest are applied to a gel, the six fragments contain 200, 120, 80, 40, 20 and 10 ng of DNA.

### *Example 2*

#### *Construction of a NotI Marker Ladder*

A marker ladder can be constructed from PCR products. The sizes of the resulting DNAs can be selected by positioning the PCR primers appropriately. In addition, the incorporation of restriction sites in the primers, which are absent in the template molecules that are amplified during PCR, allows the ends of the PCR products to be cleaved with cognate restriction enzymes. If multiple PCR product DNAs are joined together and transformed into bacteria, and if one or more of the PCR products contains an origin of replication and a selection marker, the joined molecule can be recovered from the bacteria as a recombinant molecule. Digestion of the molecule with the restriction enzyme whose sites have been placed in the primers yields the desired fragments. By using a variety of restriction enzyme sites to link PCR products, and a different restriction enzyme to cleave the resulting recombinant plasmid, multiple DNAs can be joined together in a particular order to give the desired product.

Using these principles, a marker plasmid can be constructed as follows. Three PCR products are synthesized. Terminal restriction sites allow joining the fragments in a unique order and orientation. *Not*I sites will be used to release the three desired fragments from the resulting plasmid. Spacers at the ends of the PCR products ensure efficient restriction enzyme cutting.

- 12 -

5

PCR product I, 2026 bp from pUC:	
Left primer [SEQ ID NO:7]:	<u>Nsp V</u> <u>Not I</u> <u>pUC19 coord. 637 - 656</u> 5' 10 nt spacer/tt^cgaa/gc^ggccgg/taa tga atc ggc caa cgc gc 3'
Right primer [SEQ ID NO:8]:	<u>BssH I</u> <u>pUC 19 coord. 2622 - 2603</u> 5' 10 nt spacer/g^cgcg/ga cgt cag gtg gca ctt ttc 3'

10

PCR product II, 1026 bp from SV40 DNA:	
Left primer [SEQ ID NO:9]:	<u>Mlu I</u> <u>Not I</u> <u>SV40 coord. 108 - 129</u> 5' 10 nt spacer/a^cgct/gc^ggccgc/ggt tgc tga cta att gag atg c 3'
Right primer [SEQ ID NO:10]:	<u>BamH I</u> <u>SV40 coord. 1093 - 1074</u> 5' 10 nt spacer/g^gatcc/gtg agg tga gcc tag gaa tg 3'

15

PCR product III, 526 bp from adenovirus 2:	
Left primer [SEQ ID NO:11]:	<u>Bgl II</u> <u>Not I</u> <u>Ad2 coord. 1022 - 1041</u> 5' 10 nt spacer/a^gatct/gc^ggccgc/ggt ctt gtc att atc acc gg 3'
Right primer [SEQ ID NO:12]:	<u>Cla I</u> <u>Ad2 coord. 1507-1488</u> 5' 10 nt spacer/at^cgat/gtt gcc cag act cgt taa gc 3'

Each PCR product is digested with the two enzymes that cut at each end, i.e., I + Nsp V and BssH II, II with Mlu I and BamH I, and III with Bgl II and Cla I. The three digested products are mixed and joined, and the products are digested with the six restriction enzymes prior to transformation into *E. coli*. The amplified fragments must be chosen to lack internal sites for these enzymes. The only clones that should be produced by this process should be 3500 bp plasmids which can be cleaved with Not I to give three fragments of 2000, 1000, and 500 bp. Electrophoresis of 350 ng of this digest will give three bands containing 200, 100, and 50 ng DNA, respectively.

\* \* \* \* \*

All publications mentioned hereinabove are hereby incorporated in their entirety by reference.

- 13 -

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims.

5

- 14 -

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Life Technologies, Inc.  
INVENTOR: Hartley, James, L.
- (ii) TITLE OF INVENTION: Nucleic Acid Marker Ladder For  
Estimating Mass
- (iii) NUMBER OF SEQUENCES: 12
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Sterne, Kessler, Goldstein & Fox
  - (B) STREET: 1100 New York Avenue, Suite 600
  - (C) CITY: Washington
  - (D) STATE: D.C.
  - (E) COUNTRY: USA
  - (F) ZIP: 20005
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: To be assigned
  - (B) FILING DATE: Herewith
  - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 08/142,124
  - (B) FILING DATE: 28 October 1993
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Esmond, Robert W.
  - (B) REGISTRATION NUMBER: 32,893
  - (C) REFERENCE/DOCKET NUMBER: 0942.257PC00
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (202) 371-2600
  - (B) TELEFAX: (202) 371-2540

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 41 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AUCUGACCUC AUAATTTACG GAAGCATAAA GTGTAAAGCC T

41

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 38 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- 15 -

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  
AGUCACAGCU AUAATATTGG AAATGTGCGC GGAACCCC 38
- (2) INFORMATION FOR SEQ ID NO:3:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 41 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  
AUAGCUGUGA CUAATTTACT AGTGAATCCA CAGAACTAG C 41
- (2) INFORMATION FOR SEQ ID NO:4:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 41 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
ACAUCUGGAC UUAATATTAG ACATATTGAT AAGGTGGCGA G 41
- (2) INFORMATION FOR SEQ ID NO:5:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 41 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:  
AAGUCCAGAU GUAATTTAGG GACAGTTTGG CAAGGTTTTT A 41
- (2) INFORMATION FOR SEQ ID NO:6:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 42 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:  
AUGAGGUCAG AUAATATTTA AGCCTTTTGG ATGTTTCATCA GG 42
- (2) INFORMATION FOR SEQ ID NO:7:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 34 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: both  
(D) TOPOLOGY: both



- 16 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TTCGAAGCGG CCGGTAATGA ATCGGCCAAC GCGC

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GCGCGCGACG TCAGGTGGCA CTTTTC

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 36 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ACGCGTGCGG CCGCGGTTGC TGACTAATTG AGATGC

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGATCCGTGA GGTGAGCCTA GGAATG

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 34 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both
  - (D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AGATCTGCGG CCGCGGTCTT GTCATTATCA CCGG

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: both

- 17 -

(D) TOPOLOGY: both

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

ATCGATGTTG CCCAGACTCG TTAAGC

26

***What Is Claimed Is:***

1. A nucleic acid marker ladder consisting essentially of a restriction endonuclease digest, wherein
  - (a) the nucleic acid restriction endonuclease digest is a collection of nucleic acid fragments resulting from the complete digestion of one or more nucleic acids by one or more restriction endonucleases;
  - (b) the restriction endonuclease digest contains at least 3 fragments; and
  - (c) the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.
2. The nucleic acid marker ladder according to claim 1, wherein the integer is 10.
3. The nucleic acid marker ladder according to claim 1, wherein the integer is 25.
4. The nucleic acid marker ladder according to claim 1, wherein the integer is 50.
5. The nucleic acid marker ladder according to claim 1, wherein the integer is 100.
6. The nucleic acid marker ladder according to claim 1, wherein the collection of nucleic acid fragments results from digestion of a nucleic acid by one restriction endonuclease.

- 19 -

7. A nucleic acid marker kit comprising a carrier means having in close confinement therein at least one container means where the first container means contains a nucleic acid marker ladder consisting essentially of a restriction endonuclease digest, wherein

(a) the nucleic acid restriction endonuclease digest is a collection of nucleic acid fragments resulting from the complete digestion of one or more nucleic acids by one or more restriction endonucleases;

(b) the restriction endonuclease digest contains at least 3 fragments;  
and

(c) the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.

8. The nucleic acid marker kit according to claim 7, wherein the integer is 10.

9. The nucleic acid marker kit according to claim 7, wherein the integer is 25.

10. The nucleic acid marker kit according to claim 7, wherein the integer is 50.

11. The nucleic acid marker kit according to claim 7, wherein the integer is 100.

12. The nucleic acid marker kit according to claim 7, wherein the collection of nucleic acid fragments results from digestion of a nucleic acid by one restriction endonuclease.

- 20 -

13. A method of preparing a nucleic acid marker ladder comprising:

(a) generating at least two polymerase chain reaction (PCR) products wherein each product is generated from a template comprising a restriction endonuclease site and a primer comprising the restriction endonuclease site in the template;

(b) joining the PCR products to produce a nucleic acid molecule;  
and

(c) completely digesting one or more nucleic acid molecules with at least one restriction endonuclease

wherein a nucleic acid marker ladder is produced wherein the ladder contains at least 3 fragments and the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more.

14. A method of using a nucleic acid marker ladder to estimate the mass of a nucleic acid comprising:

(a) electrophoresing a known amount of the marker ladder of claim 1 and an unknown amount of said nucleic acid on an agarose gel; and

(b) comparing the mass of said marker ladder with the mass of said nucleic acid.

1/2




FIGURE 1




FIGURE 2

# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/US 94/12505

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C12N15/10 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,93 14224 (APPLIED BIOSYSTEMS, INC.) 22 July 1993 the whole document ---	1-14
A	WO,A,91 18095 (BOARD REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 28 November 191 the whole document ---	1-14
A	EP,A,0 466 404 (LIFE TECHNOLOGIES INC.) 15 January 1992 the whole document ---	1-14
A	US,A,4 403 036 (HARTLEY ET AL.) 6 September 1983 see column 9, line 57 - column 10, line 22 --- -/--	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

**\* Special categories of cited documents :**

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

24 February 1995

Date of mailing of the international search report

0 6. 03. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Hornig, H



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/12505

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,5 137 814 (RASHTCHIAN ET AL.) 11 August 1992 cited in the application the whole document -----	1-14

## INTERNATIONAL SEARCH REPORT

Information: Patent family members

Intern: Application No

PCT/UJ 94/12505

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9314224	22-07-93	NONE	
WO-A-9118095	28-11-91	US-A- 5162514 EP-A- 0533750 US-A- 5233030	10-11-92 31-03-93 03-08-93
EP-A-0466404	15-01-92	US-A- 5316908 CA-A- 2045794	31-05-94 14-01-92
US-A-4403036	06-09-83	NONE	
US-A-5137814	11-08-92	CA-A- 2088766 EP-A- 0544894 JP-T- 6500702 WO-A- 9222649 US-A- 5229283	15-12-92 09-06-93 27-01-94 23-12-92 20-07-93